首页> 外文期刊>European journal of pain : >Genomic variations and transcriptional regulation of the human mu-opioid receptor gene.
【24h】

Genomic variations and transcriptional regulation of the human mu-opioid receptor gene.

机译:人类mu阿片受体基因的基因组变异和转录调控。

获取原文
获取原文并翻译 | 示例
       

摘要

The mu-opioid receptor (MOR1) is a target of endogenous and exogenous opioids and plays a pivotal role for anesthesia and analgesia. Variations in the 5' flanking sequence of the mu-opioid receptor gene may influence transcriptional regulation and ultimately alter protein expression of MOR1. In the present study we investigated the influence of eight single nucleotide polymorphisms (SNP) within the mu-opioid receptor promoter on promoter activity and evaluated the frequencies of the relevant SNPs in 700 patients under opioid medication. Reporter-gene-constructs were created by means of PCR and site directed mutagenesis, testing eight SNPs previously described. The neuroblastoma cell line SHSY5Y was used for transfection and promoter activity was estimated by luciferase activity. Of the eight reporter gene constructs employed to test genomic variations, two produced a significant change in luciferase activity when compared to wild-type constructs. The G-554A variation located within a known NFkB bindingelement resulted in a decreased activity whereas the A/G base exchange at position -1320 showed an increased luciferase activity. This particular variant generated a myeloid zinc finger (MZF1) cis-acting element known to impact transcription. The allele frequency of the -1320G variant was 0.21% in 700 Caucasian patients under opioid medication in contrast to 9.1% reported previously in drug addicted African Americans. Because of this unexpected low frequency an association analysis to opioid requirements and effects of mu-opioid receptor agonists was not feasible. In conclusion, transcriptional regulation of MOR1 is modified by two genetic variations at positions -554 and -1320 of the mu-opioid receptor promoter. Individuals presenting these variations may have an altered level of MOR expression. A possible association of these genomic variants on efficacy and side effects of opioid treatment in different ethnic groups has to be elucidated.
机译:mu-阿片受体(MOR1)是内源性和外源性阿片的靶标,在麻醉和镇痛中起着关键作用。 mu阿片受体基因5'侧翼序列的变异可能影响转录调控,并最终改变MOR1的蛋白质表达。在本研究中,我们调查了阿片类药物受体启动子内的8个单核苷酸多态性(SNP)对启动子活性的影响,并评估了700名接受阿片类药物治疗的患者中相关SNP的频率。通过PCR和定点诱变创建记者基因构建体,测试先前描述的八个SNP。将神经母细胞瘤细胞系SHSY5Y用于转染,并通过荧光素酶活性评估启动子活性。与野生型构建体相比,用于测试基因组变异的八个报告基因构建体中,有两个在荧光素酶活性方面产生了显着变化。位于已知NFkB结合元件内的G-554A变异导致活性降低,而在-1320位的A / G碱基交换表明荧光素酶活性增加。这个特定的变体生成了已知影响转录的髓样锌指(MZF1)顺式作用元件。在700名接受阿片类药物治疗的白种人患者中,-1320G变体的等位基因频率为0.21%,而先前在吸毒成瘾的非洲裔美国人中报道的9.1%。由于这种出乎意料的低频,对阿片类药物的需求和对阿片类药物受体激动剂的影响进行关联分析是不可行的。总之,MOR1的转录调控被μ阿片受体启动子的-554和-1320位置的两个遗传变异所修饰。表现出这些变异的个体可能具有改变的MOR表达水平。必须阐明这些基因组变体在不同族裔群体中对阿片类药物治疗的功效和副作用的可能关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号